uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q16.541 | Q16 | What Small molecule therapies have been approved by the FDA to treat Marfan syndrome? | There are no drug Small molecule therapies approved to treat Marfan syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "marfan syndrome" OR LOWER(mesh_heading) = "marfan syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.766 | Q16 | What Small molecule therapies have been approved by the FDA to treat angiomyolipoma? | Everolimus is the only Small molecule therapy approved by the FDA to treat angiomyolipoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "angiomyolipoma" OR LOWER(mesh_heading) = "angiomyolipoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084964', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1084968', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085099', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085103', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085234', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085238', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085369', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085373', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085504', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085508', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085639', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085643', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085774', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085778', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085909', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085913', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086044', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086048', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086179', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086183', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086314', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086318', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086449', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086453', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086584', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086588', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086719', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086723', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086854', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086858', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086989', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086993', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087124', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087128', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087259', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087263', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087394', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087398', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087529', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087533', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087664', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087668', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087799', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087803', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087934', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087938', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088069', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088073', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088204', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088208', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088339', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088343', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088474', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088478', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088609', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088613', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088744', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088748', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088879', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088883', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089014', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089018', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089149', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089153', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089284', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089288', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089419', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089423', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089554', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089558', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089689', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089693', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089824', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089828', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089959', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089963', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090094', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090098', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090229', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090233', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090364', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090368', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090499', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090503', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090634', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090638', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1071 | Q16 | What Small molecule therapies have been approved by the FDA to treat fibromatosis? | There are no drug Small molecule therapies approved to treat fibromatosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fibromatosis" OR LOWER(mesh_heading) = "fibromatosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1208 | Q16 | What Small molecule therapies have been approved by the FDA to treat interstitial nephritis? | There are no drug Small molecule therapies approved to treat interstitial nephritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "interstitial nephritis" OR LOWER(mesh_heading) = "interstitial nephritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.247 | Q16 | What Protein therapies have been approved by the FDA to treat osteogenesis imperfecta? | There are no drug Protein therapies approved to treat osteogenesis imperfecta. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "osteogenesis imperfecta" OR LOWER(mesh_heading) = "osteogenesis imperfecta") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1136 | Q16 | What Small molecule therapies have been approved by the FDA to treat hemophagocytic syndrome? | There are no drug Small molecule therapies approved to treat hemophagocytic syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hemophagocytic syndrome" OR LOWER(mesh_heading) = "hemophagocytic syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.792 | Q16 | What Small molecule therapies have been approved by the FDA to treat astrocytoma? | Everolimus is the only Small molecule therapy approved by the FDA to treat astrocytoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "astrocytoma" OR LOWER(mesh_heading) = "astrocytoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084953', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1084960', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1084970', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085088', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085095', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085105', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085223', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085230', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085240', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085358', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085365', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085375', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085493', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085500', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085510', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085628', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085635', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085645', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085763', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085770', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085780', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085898', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085905', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085915', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086033', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086040', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086050', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086168', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086175', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086185', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086303', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086310', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086320', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086438', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086445', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086455', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086573', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086580', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086590', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086708', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086715', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086725', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086843', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086850', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086860', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086978', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086985', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086995', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087113', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087120', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087130', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087248', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087255', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087265', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087383', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087390', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087400', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087518', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087525', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087535', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087653', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087660', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087670', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087788', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087795', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087805', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087923', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087930', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087940', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088058', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088065', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088075', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088193', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088200', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088210', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088328', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088335', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088345', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088463', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088470', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088480', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088598', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088605', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088615', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088733', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088740', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088750', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088868', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088875', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088885', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089003', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089010', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089020', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089138', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089145', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089155', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089273', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089280', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089290', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089408', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.493 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hot flashes? | There are no drug Small molecule therapies approved to treat Hot flashes. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hot flashes" OR LOWER(mesh_heading) = "hot flashes") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.155 | Q16 | What Protein therapies have been approved by the FDA to treat epidermolysis bullosa? | There are no drug Protein therapies approved to treat epidermolysis bullosa. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "epidermolysis bullosa" OR LOWER(mesh_heading) = "epidermolysis bullosa") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.969 | Q16 | What Small molecule therapies have been approved by the FDA to treat cystic, mucinous, and serous neoplasm? | There are no drug Small molecule therapies approved to treat cystic, mucinous, and serous neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cystic, mucinous, and serous neoplasm" OR LOWER(mesh_heading) = "cystic, mucinous, and serous neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.861 | Q16 | What Small molecule therapies have been approved by the FDA to treat carcinoid syndrome? | There are no drug Small molecule therapies approved to treat carcinoid syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "carcinoid syndrome" OR LOWER(mesh_heading) = "carcinoid syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1323 | Q16 | What Small molecule therapies have been approved by the FDA to treat migraine without aura? | There are no drug Small molecule therapies approved to treat migraine without aura. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "migraine without aura" OR LOWER(mesh_heading) = "migraine without aura") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.629 | Q16 | What Small molecule therapies have been approved by the FDA to treat Smith-Magenis syndrome? | Tasimelteon is the only Small molecule therapy approved by the FDA to treat Smith-Magenis syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "smith-magenis syndrome" OR LOWER(mesh_heading) = "smith-magenis syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094674', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094675', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094682', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094683', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094690', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094691', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094698', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094699', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094706', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094707', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094714', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094715', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094722', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094723', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094730', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094731', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094738', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094739', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094746', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094747', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094754', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094755', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094762', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094763', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094770', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094771', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094778', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094779', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094786', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094787', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094794', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094795', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094802', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094803', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094810', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094811', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094818', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094819', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094826', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094827', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094834', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094835', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094842', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094843', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094850', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094851', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094858', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094859', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094866', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094867', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094874', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094875', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094882', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094883', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094890', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094891', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094898', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094899', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094906', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094907', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094914', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094915', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094922', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094923', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094930', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094931', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094938', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094939', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094946', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094947', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094954', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094955', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094962', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094963', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094970', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094971', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094978', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094979', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094986', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094987', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1094994', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094995', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1095002', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1095003', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1095010', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1095011', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1095018', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1095019', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1095026', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1095027', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000168412', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1095034', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000134640', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1095035', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000134640', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1095042', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000134640', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1095043', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000134640', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1095050', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000134640', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1095051', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000134640', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1095058', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000134640', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1095059', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000134640', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}, {'UUID': 'DrugTargetsIndication121923_text_1095066', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000134640', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1095067', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000134640', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.690 | Q16 | What Small molecule therapies have been approved by the FDA to treat Zollinger-Ellison Syndrome? | There are 2 Small molecule therapy drugs that are approved to treat Zollinger-Ellison Syndrome which are as follows: Pantoprazole Sodium and Esomeprazole Magnesium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "zollinger-ellison syndrome" OR LOWER(mesh_heading) = "zollinger-ellison syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097748', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097753', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097758', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097763', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097768', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097773', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097778', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097783', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097788', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097793', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097798', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097803', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097808', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097813', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097818', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097823', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097828', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097833', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097838', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097843', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097848', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097853', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097863', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097875', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097887', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1097899', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1570 | Q16 | What Small molecule therapies have been approved by the FDA to treat renal carcinoma? | Axitinib is the only Small molecule therapy approved by the FDA to treat renal carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "renal carcinoma" OR LOWER(mesh_heading) = "renal carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_689158', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689200', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689242', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689284', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689326', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689368', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689410', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689452', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689494', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689536', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689578', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689620', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689662', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689704', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689746', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689788', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689830', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689872', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689914', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689956', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_689998', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_690040', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_690082', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_690124', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.573 | Q16 | What Small molecule therapies have been approved by the FDA to treat Olfactory Neuroblastoma? | There are no drug Small molecule therapies approved to treat Olfactory Neuroblastoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "olfactory neuroblastoma" OR LOWER(mesh_heading) = "olfactory neuroblastoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1676 | Q16 | What Small molecule therapies have been approved by the FDA to treat syphilis? | There are no drug Small molecule therapies approved to treat syphilis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "syphilis" OR LOWER(mesh_heading) = "syphilis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.18 | Q16 | What Protein therapies have been approved by the FDA to treat Abnormality of blood and blood-forming tissues? | There are no drug Protein therapies approved to treat Abnormality of blood and blood-forming tissues. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "abnormality of blood and blood-forming tissues" OR LOWER(mesh_heading) = "abnormality of blood and blood-forming tissues") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.128 | Q16 | What Protein therapies have been approved by the FDA to treat chronic myelogenous leukemia? | There are no drug Protein therapies approved to treat chronic myelogenous leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic myelogenous leukemia" OR LOWER(mesh_heading) = "chronic myelogenous leukemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1359 | Q16 | What Small molecule therapies have been approved by the FDA to treat narcolepsy? | There are 2 Small molecule therapy drugs that are approved to treat narcolepsy which are as follows: Armodafinil and Sodium Oxybate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "narcolepsy" OR LOWER(mesh_heading) = "narcolepsy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_418362', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418375', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418388', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418401', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418414', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418427', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418440', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418453', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418466', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418479', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418492', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418505', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418518', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418531', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418544', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418557', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418570', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418583', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418596', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418609', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418622', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418635', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418648', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418661', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418674', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418687', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418700', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418713', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418726', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418739', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418752', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418765', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418778', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418791', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418804', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418817', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418830', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418843', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418856', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418869', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418882', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418895', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418908', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418921', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418934', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418947', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418960', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418973', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418986', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418999', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419012', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419025', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419038', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419051', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419064', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419077', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419090', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419103', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419116', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419129', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439211', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439242', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439273', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439304', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439335', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439366', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439397', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439428', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439459', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439490', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439521', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439552', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439583', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439614', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439645', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439676', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439707', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439738', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439769', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439800', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439831', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439862', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439893', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439924', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439955', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439986', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440017', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440048', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440079', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440110', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440141', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440172', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440203', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440234', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440265', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440296', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440327', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440358', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440389', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440420', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1289 | Q16 | What Small molecule therapies have been approved by the FDA to treat malignant pleural mesothelioma? | Pemetrexed is the only Small molecule therapy approved by the FDA to treat malignant pleural mesothelioma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "malignant pleural mesothelioma" OR LOWER(mesh_heading) = "malignant pleural mesothelioma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_918480', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918543', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918606', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918669', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918732', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918795', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918858', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918921', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918984', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919047', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919110', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919173', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919236', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919299', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919362', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1732 | Q16 | What Small molecule therapies have been approved by the FDA to treat urogenital neoplasm? | There are no drug Small molecule therapies approved to treat urogenital neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "urogenital neoplasm" OR LOWER(mesh_heading) = "urogenital neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.935 | Q16 | What Small molecule therapies have been approved by the FDA to treat cocaine dependence? | There are no drug Small molecule therapies approved to treat cocaine dependence. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cocaine dependence" OR LOWER(mesh_heading) = "cocaine dependence") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.988 | Q16 | What Small molecule therapies have been approved by the FDA to treat diabetic nephropathy? | There are no drug Small molecule therapies approved to treat diabetic nephropathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "diabetic nephropathy" OR LOWER(mesh_heading) = "diabetic nephropathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1728 | Q16 | What Small molecule therapies have been approved by the FDA to treat urgency urinary incontinence? | There are 4 Small molecule therapy drugs that are approved to treat urgency urinary incontinence which are as follows: Solifenacin Succinate, Fesoterodine Fumarate, Mirabegron, and Vibegron. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "urgency urinary incontinence" OR LOWER(mesh_heading) = "urgency urinary incontinence") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857279', 'drugName': 'Solifenacin Succinate', 'tradeNames_list': "['Solifenacin succinate', 'Vesicare', 'Vesicare ls']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857282', 'drugName': 'Solifenacin Succinate', 'tradeNames_list': "['Solifenacin succinate', 'Vesicare', 'Vesicare ls']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857293', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857296', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857299', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857302', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857305', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857308', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857311', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857314', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857317', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857320', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857323', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857326', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857329', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857332', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857335', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857338', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857341', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857344', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857347', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857350', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857353', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857356', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857359', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857362', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857365', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857368', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857371', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857374', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857377', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857380', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857383', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_857386', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181072', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937694', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937710', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937726', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937742', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937758', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937774', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937790', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937806', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937822', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937838', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937854', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937870', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937886', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937902', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937918', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937934', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937950', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937966', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937982', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_937998', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938014', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938030', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938046', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938062', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938078', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938094', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938110', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938126', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938142', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938158', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938174', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938190', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938206', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938222', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938238', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938254', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938260', 'drugName': 'Vibegron', 'tradeNames_list': "['Gemtesa']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}, {'UUID': 'DrugTargetsIndication121923_text_938265', 'drugName': 'Vibegron', 'tradeNames_list': "['Gemtesa']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.191 | Q16 | What Protein therapies have been approved by the FDA to treat ischemia reperfusion injury? | There are no drug Protein therapies approved to treat ischemia reperfusion injury. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ischemia reperfusion injury" OR LOWER(mesh_heading) = "ischemia reperfusion injury") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1148 | Q16 | What Small molecule therapies have been approved by the FDA to treat heroin dependence? | There are no drug Small molecule therapies approved to treat heroin dependence. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "heroin dependence" OR LOWER(mesh_heading) = "heroin dependence") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1000 | Q16 | What Small molecule therapies have been approved by the FDA to treat dilated cardiomyopathy? | There are no drug Small molecule therapies approved to treat dilated cardiomyopathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dilated cardiomyopathy" OR LOWER(mesh_heading) = "dilated cardiomyopathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1719 | Q16 | What Small molecule therapies have been approved by the FDA to treat ulcerative colitis? | There are 6 Small molecule therapy drugs that are approved to treat ulcerative colitis which are as follows: Prednisone, Budesonide, Dexamethasone, Hydrocortisone, Balsalazide Disodium, and Mesalamine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ulcerative colitis" OR LOWER(mesh_heading) = "ulcerative colitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217635', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_217843', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_218051', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_218259', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_218467', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_218675', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_218883', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_219091', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_219299', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_219507', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_219715', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_219923', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_220131', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_220339', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_220547', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_220755', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222389', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222434', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222479', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222524', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222569', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222614', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222659', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222704', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222749', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222794', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222839', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222884', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222929', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_222974', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223019', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223064', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223109', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223154', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223199', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223244', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223289', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223334', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223379', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223424', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223469', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223514', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223559', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223604', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223649', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223694', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223739', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223784', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223829', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223874', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223919', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_223964', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224009', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224054', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224099', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224144', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224189', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224234', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224279', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224324', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224369', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224414', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224459', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224504', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224549', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224594', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224639', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224684', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224729', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224774', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224819', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224864', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224909', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224954', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_224999', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_225044', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_225089', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_225134', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_225179', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_225224', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_225269', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_225314', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_225359', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_225404', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_226329', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_226614', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_226899', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_227184', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_227469', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_227754', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_228039', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_228324', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_228609', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_228894', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_229179', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_229464', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_229749', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_230034', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_230319', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}, {'UUID': 'DrugTargetsIndication121923_text_230604', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1462 | Q16 | What Small molecule therapies have been approved by the FDA to treat peripheral arterial disease? | Vorapaxar Sulfate is the only Small molecule therapy approved by the FDA to treat peripheral arterial disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "peripheral arterial disease" OR LOWER(mesh_heading) = "peripheral arterial disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193356', 'drugName': 'Vorapaxar Sulfate', 'tradeNames_list': "['Zontivity']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181104', 'approvedSymbol': 'F2R', 'approvedName': 'coagulation factor II thrombin receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peripheral Arterial Disease', 'efo_term': 'peripheral arterial disease'}, {'UUID': 'DrugTargetsIndication121923_text_1193360', 'drugName': 'Vorapaxar Sulfate', 'tradeNames_list': "['Zontivity']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000181104', 'approvedSymbol': 'F2R', 'approvedName': 'coagulation factor II thrombin receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peripheral Arterial Disease', 'efo_term': 'peripheral arterial disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.610 | Q16 | What Small molecule therapies have been approved by the FDA to treat Recurrent tonsillitis? | There are no drug Small molecule therapies approved to treat Recurrent tonsillitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "recurrent tonsillitis" OR LOWER(mesh_heading) = "recurrent tonsillitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.181 | Q16 | What Protein therapies have been approved by the FDA to treat infection? | There are no drug Protein therapies approved to treat infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "infection" OR LOWER(mesh_heading) = "infection") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.303 | Q16 | What Protein therapies have been approved by the FDA to treat systemic inflammatory response syndrome? | There are no drug Protein therapies approved to treat systemic inflammatory response syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "systemic inflammatory response syndrome" OR LOWER(mesh_heading) = "systemic inflammatory response syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.500 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hyperhidrosis? | There are no drug Small molecule therapies approved to treat Hyperhidrosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hyperhidrosis" OR LOWER(mesh_heading) = "hyperhidrosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1595 | Q16 | What Small molecule therapies have been approved by the FDA to treat salivary gland cancer? | There are no drug Small molecule therapies approved to treat salivary gland cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "salivary gland cancer" OR LOWER(mesh_heading) = "salivary gland cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1566 | Q16 | What Small molecule therapies have been approved by the FDA to treat refractive error? | There are no drug Small molecule therapies approved to treat refractive error. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "refractive error" OR LOWER(mesh_heading) = "refractive error") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1467 | Q16 | What Small molecule therapies have been approved by the FDA to treat peripheral vertigo? | There are no drug Small molecule therapies approved to treat peripheral vertigo. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "peripheral vertigo" OR LOWER(mesh_heading) = "peripheral vertigo") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1552 | Q16 | What Small molecule therapies have been approved by the FDA to treat pulmonary sarcoidosis? | There are no drug Small molecule therapies approved to treat pulmonary sarcoidosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pulmonary sarcoidosis" OR LOWER(mesh_heading) = "pulmonary sarcoidosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.521 | Q16 | What Small molecule therapies have been approved by the FDA to treat Juvenile Myelomonocytic Leukemia? | There are no drug Small molecule therapies approved to treat Juvenile Myelomonocytic Leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "juvenile myelomonocytic leukemia" OR LOWER(mesh_heading) = "juvenile myelomonocytic leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1078 | Q16 | What Small molecule therapies have been approved by the FDA to treat focal segmental glomerulosclerosis? | There are no drug Small molecule therapies approved to treat focal segmental glomerulosclerosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "focal segmental glomerulosclerosis" OR LOWER(mesh_heading) = "focal segmental glomerulosclerosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.480 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hepatic steatosis? | There are no drug Small molecule therapies approved to treat Hepatic steatosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hepatic steatosis" OR LOWER(mesh_heading) = "hepatic steatosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.158 | Q16 | What Protein therapies have been approved by the FDA to treat fallopian tube cancer? | There are no drug Protein therapies approved to treat fallopian tube cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fallopian tube cancer" OR LOWER(mesh_heading) = "fallopian tube cancer") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1253 | Q16 | What Small molecule therapies have been approved by the FDA to treat lichen planus? | There are no drug Small molecule therapies approved to treat lichen planus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lichen planus" OR LOWER(mesh_heading) = "lichen planus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1204 | Q16 | What Small molecule therapies have been approved by the FDA to treat intermittent vascular claudication? | There are no drug Small molecule therapies approved to treat intermittent vascular claudication. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intermittent vascular claudication" OR LOWER(mesh_heading) = "intermittent vascular claudication") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.17 | Q16 | What Protein therapies have been approved by the FDA to treat Abdominal Aortic Aneurysm? | There are no drug Protein therapies approved to treat Abdominal Aortic Aneurysm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "abdominal aortic aneurysm" OR LOWER(mesh_heading) = "abdominal aortic aneurysm") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1081 | Q16 | What Small molecule therapies have been approved by the FDA to treat folliculitis? | There are no drug Small molecule therapies approved to treat folliculitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "folliculitis" OR LOWER(mesh_heading) = "folliculitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1735 | Q16 | What Small molecule therapies have been approved by the FDA to treat uterine cancer? | There are no drug Small molecule therapies approved to treat uterine cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "uterine cancer" OR LOWER(mesh_heading) = "uterine cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.550 | Q16 | What Small molecule therapies have been approved by the FDA to treat Mitral regurgitation? | There are no drug Small molecule therapies approved to treat Mitral regurgitation. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mitral regurgitation" OR LOWER(mesh_heading) = "mitral regurgitation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.662 | Q16 | What Small molecule therapies have been approved by the FDA to treat Torticollis? | There are no drug Small molecule therapies approved to treat Torticollis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "torticollis" OR LOWER(mesh_heading) = "torticollis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1435 | Q16 | What Small molecule therapies have been approved by the FDA to treat pachyonychia congenita? | There are no drug Small molecule therapies approved to treat pachyonychia congenita. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pachyonychia congenita" OR LOWER(mesh_heading) = "pachyonychia congenita") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1027 | Q16 | What Small molecule therapies have been approved by the FDA to treat enuresis? | There are no drug Small molecule therapies approved to treat enuresis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "enuresis" OR LOWER(mesh_heading) = "enuresis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1468 | Q16 | What Small molecule therapies have been approved by the FDA to treat peritoneal neoplasm? | Niraparib Tosylate is the only Small molecule therapy approved by the FDA to treat peritoneal neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "peritoneal neoplasm" OR LOWER(mesh_heading) = "peritoneal neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823336', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_823340', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_823344', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_823348', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_823352', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_823356', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_823360', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143799', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_823364', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143799', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_823368', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143799', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_823372', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143799', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_823376', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143799', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_823380', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143799', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.967 | Q16 | What Small molecule therapies have been approved by the FDA to treat cutaneous melanoma? | There are 5 Small molecule therapy drugs that are approved to treat cutaneous melanoma which are as follows: Vemurafenib, Encorafenib, Dabrafenib Mesylate, Binimetinib, and Trametinib Dimethyl Sulfoxide. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cutaneous melanoma" OR LOWER(mesh_heading) = "cutaneous melanoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752095', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752116', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752137', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752158', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752179', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752200', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752221', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752236', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752250', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752264', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752278', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752292', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752306', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752320', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752334', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752348', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752362', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752376', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752390', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752404', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752418', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752432', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752446', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752460', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752474', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752488', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752502', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752516', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752530', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752544', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752558', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752572', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752586', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752600', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752614', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752628', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752642', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752656', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752670', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752676', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752683', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752690', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752697', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752704', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752711', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752718', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752725', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752732', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752739', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752746', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752753', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752760', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752767', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752774', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752781', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752788', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752795', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752802', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752809', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752816', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752823', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752830', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752837', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752844', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752851', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752858', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752865', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752872', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752879', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752886', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752893', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752900', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752907', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752914', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752921', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752928', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752935', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752942', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752949', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752956', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752963', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752970', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752977', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926652', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926678', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926704', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926730', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926756', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926782', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926808', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926834', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926860', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926886', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926912', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926938', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926964', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926990', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_927016', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_927042', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_927068', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1656 | Q16 | What Small molecule therapies have been approved by the FDA to treat squamous cell intraepithelial neoplasia? | There are no drug Small molecule therapies approved to treat squamous cell intraepithelial neoplasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "squamous cell intraepithelial neoplasia" OR LOWER(mesh_heading) = "squamous cell intraepithelial neoplasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.285 | Q16 | What Protein therapies have been approved by the FDA to treat rheumatoid arthritis? | Cyclosporine is the only Protein therapy approved by the FDA to treat rheumatoid arthritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "rheumatoid arthritis" OR LOWER(mesh_heading) = "rheumatoid arthritis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100647', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1100774', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1100901', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1101028', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1101155', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1101282', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1101409', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1101536', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1101663', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1101790', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1101917', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1102044', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1102171', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1102298', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1102425', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1102552', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1102679', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1102806', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1102933', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}, {'UUID': 'DrugTargetsIndication121923_text_1103060', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q17.589 | Q17 | What gene does the drug Trandolapril target? | The drug Trandolapril targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trandolapril%" OR LOWER(tradeNames_string) LIKE "%trandolapril%" OR LOWER(drugSynonyms_string) LIKE "%trandolapril%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3055', 'drugName': 'Trandolapril', 'tradeNames_string': 'Gopten, Mavik, Odrik, Trandolapril', 'drugSynonyms_string': 'Indolapril, NSC-758939, RU 44570, RU-44570, Trandolapril', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1868 | Q17 | What gene does the drug Hydromorphone target? | The drug Hydromorphone targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydromorphone%" OR LOWER(tradeNames_string) LIKE "%hydromorphone%" OR LOWER(drugSynonyms_string) LIKE "%hydromorphone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_245', 'drugName': 'Morphine', 'tradeNames_string': '', 'drugSynonyms_string': 'Anhydrous morphine, Avinza, Depodur, Hydromorphone hydrochloride impurity, morphine-, IDS-NM-009, Infumorph, Kadian, Morphia, Morphine, Morphine (anhydrous), Morphine anhydrous, Morphine extended release, Morphine polistirex, Morphium, N02AA01, Nepenthe, Ospalivina', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Rheumatic Disease (EFO_0005755), Hemorrhage (MP_0001914), Pain (EFO_0003843), Neonatal Abstinence Syndrome (EFO_0005799), Obesity (EFO_0001073), Pulmonary Arterial Hypertension (EFO_0001361), Injury (EFO_0000546), Idiopathic Pulmonary Fibrosis (EFO_0000768), Pregnancy (EFO_0002950), Nephrolithiasis (EFO_0004253), Prostate Cancer (MONDO_0008315), Rotator Cuff Tear (EFO_1001250), Osteoarthritis, Knee (EFO_0004616), Neuropathic Pain (EFO_0005762), Acute Myocardial Infarction (EFO_0008583), Acute Myeloid Leukemia (EFO_0000222), Scoliosis (EFO_0004273), Respiratory Depression (EFO_0009842), Rib Fracture (EFO_0009620), Bone Fracture (EFO_0003931), Pruritus (HP_0000989), Heroin Dependence (EFO_0004240), Restless Legs Syndrome (EFO_0004270), Cardiac Arrest (EFO_0009492), Drug Dependence (EFO_0003890), Premature Birth (EFO_0003917), Renal Colic (EFO_1001412), Sickle Cell Anemia (MONDO_0011382), Chronic Obstructive Pulmonary Disease (EFO_0000341), Back Pain (HP_0003418), Myocardial Infarction (EFO_0000612), Constipation (HP_0002019), Obstructive Sleep Apnea (EFO_0003918), Recurrent Tonsillitis (HP_0011110), Opioid Dependence (EFO_0005611), Shortness Of Breath (EFO_0009727), Head And Neck Malignant Neoplasia (EFO_0006859), Opioid Use Disorder (EFO_0010702), Neoplasm (EFO_0000616), Post-Operative Sign Or Symptom (EFO_0005323), Adenocarcinoma (EFO_0000228), Stomatitis (EFO_0009688), Chronic Pain (HP_0012532), Blood Coagulation Disease (EFO_0009314), Mucositis (EFO_1001898), Hallux Valgus (HP_0001822), Low Back Pain (HP_0003419), Multiple Bone Fractures (EFO_0009513)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3034', 'drugName': 'Hydromorphone', 'tradeNames_string': '', 'drugSynonyms_string': 'Dilaudid, Dilaudid-HP, Dimorphone, Hydromorphon, Hydromorphone, IDS-NH-004, Jurnista, N02AA03, NSC-19046, Novolaudon, Palladone', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Opioid Use Disorder (EFO_0010702), Drug Dependence (EFO_0003890), Osteoarthritis, Hip (EFO_1000786), Liver Disease (EFO_0001421), Pain (EFO_0003843), Chronic Pain (HP_0012532), Sickle Cell Anemia (MONDO_0011382), Osteoarthritis, Knee (EFO_0004616), Back Pain (HP_0003418), Heroin Dependence (EFO_0004240), Constipation (HP_0002019), Mucositis (EFO_1001898), Low Back Pain (HP_0003419), Injury (EFO_0000546), Ileus (MONDO_0004567), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4427', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_string': 'Dilaudid, Dilaudid-hp, Exalgo, Hydromorphone hydrochloride, Palladone, Palladone-sr', 'drugSynonyms_string': 'Dihydromorphinone hydrochloride, Hydromorphone HCl, Hydromorphone hcl, Hydromorphone hydrochloride, Hydromorphone hydrochloride cii, NSC-117862', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Drug Dependence (EFO_0003890), Osteoarthritis, Hip (EFO_1000786), Liver Disease (EFO_0001421), Pain (EFO_0003843), Chronic Pain (HP_0012532), Osteoarthritis, Knee (EFO_0004616), Back Pain (HP_0003418)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1061 | Q17 | What gene does the drug Xl550 target? | The drug Xl550 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene NR3C2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xl550%" OR LOWER(tradeNames_string) LIKE "%xl550%" OR LOWER(drugSynonyms_string) LIKE "%xl550%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4029', 'drugName': 'Xl550', 'tradeNames_string': '', 'drugSynonyms_string': 'CS-3150, Esaxerenone, XL-550, Xl550', 'linkedDiseasesDrug_string': 'Primary Aldosteronism (MONDO_0001422), Hypertension (EFO_0000537), Essential Hypertension (MONDO_0001134), Diabetic Nephropathy (EFO_0000401)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1084 | Q17 | What gene does the drug Methohexital target? | The drug Methohexital targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methohexital%" OR LOWER(tradeNames_string) LIKE "%methohexital%" OR LOWER(drugSynonyms_string) LIKE "%methohexital%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_314', 'drugName': 'Methohexital', 'tradeNames_string': '', 'drugSynonyms_string': 'Methohexital, Methohexital civ, Methohexitone', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_4143', 'drugName': 'Methohexital Sodium', 'tradeNames_string': 'Brevimytal, Brevital, Brevital sodium, Brietal, Brietal sod, Methohexitone', 'drugSynonyms_string': 'Enallynymal sodium, Methohexital sodium, Methohexital sodium salt, Sodium methohexital', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.925 | Q17 | What gene does the drug Phenylephrine Bitartrate target? | The drug Phenylephrine Bitartrate targets 3 genes: ADRA1D, ADRA1B and ADRA1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phenylephrine bitartrate%" OR LOWER(tradeNames_string) LIKE "%phenylephrine bitartrate%" OR LOWER(drugSynonyms_string) LIKE "%phenylephrine bitartrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2414', 'drugName': 'Phenylephrine Bitartrate', 'tradeNames_string': '', 'drugSynonyms_string': 'Phenylephrine acid tartrate, Phenylephrine bitartrate, Phenylephrine hydrogen tartrate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.73 | Q17 | What gene does the drug Cangrelor target? | The drug Cangrelor targets the gene P2RY12. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cangrelor%" OR LOWER(tradeNames_string) LIKE "%cangrelor%" OR LOWER(drugSynonyms_string) LIKE "%cangrelor%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1075', 'drugName': 'Cangrelor Tetrasodium', 'tradeNames_string': 'Kengreal', 'drugSynonyms_string': 'AR-C69931MX, Cangrelor, Cangrelor tetrasodium, Cangrelor tetrasodium salt, Kengrexal', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'P2RY12 (ENSG00000169313)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1523', 'drugName': 'Cangrelor', 'tradeNames_string': '', 'drugSynonyms_string': 'AR-C69931XX, Cangrelor', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Coronary Artery Disease (EFO_0001645), Myocardial Infarction (EFO_0000612), Acute Coronary Syndrome (EFO_0005672), St Elevation Myocardial Infarction (EFO_0008585), Ischemia (EFO_0000556)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'P2RY12 (ENSG00000169313)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.435 | Q17 | What gene does the drug Bdtx189 target? | The drug Bdtx189 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: ERBB2 and EGFR | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bdtx189%" OR LOWER(tradeNames_string) LIKE "%bdtx189%" OR LOWER(drugSynonyms_string) LIKE "%bdtx189%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5069', 'drugName': 'Bdtx189', 'tradeNames_string': '', 'drugSynonyms_string': 'BDTX189, Bdtx-189, Bdtx189, Tuxobertinib', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5070', 'drugName': 'Bdtx189', 'tradeNames_string': '', 'drugSynonyms_string': 'BDTX189, Bdtx-189, Bdtx189, Tuxobertinib', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.911 | Q17 | What gene does the drug Midostaurin target? | The drug Midostaurin targets 16 genes: PRKCD, FLT3, PRKCE, KIT, PRKCI, PRKCH, PRKCZ, KDR, PRKCA, PRKCQ, PRKD3, PRKCG, PDGFRB, PRKD1, PRKCB and PDGFRA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%midostaurin%" OR LOWER(tradeNames_string) LIKE "%midostaurin%" OR LOWER(drugSynonyms_string) LIKE "%midostaurin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5667', 'drugName': 'Midostaurin', 'tradeNames_string': 'Rydapt', 'drugSynonyms_string': 'CGP 41251, CGP-41251, Midostaurin, NSC-656576, NVP-PKC412, PKC 412, PKC-412, Pkc-412', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Liver Disease (EFO_0001421), Acute Lymphoblastic Leukemia (EFO_0000220), Mastocytosis (EFO_0009001), Systemic Mastocytosis (MONDO_0016586), Acute Myeloid Leukemia (EFO_0000222), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_5664', 'drugName': 'Midostaurin', 'tradeNames_string': 'Rydapt', 'drugSynonyms_string': 'CGP 41251, CGP-41251, Midostaurin, NSC-656576, NVP-PKC412, PKC 412, PKC-412, Pkc-412', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Liver Disease (EFO_0001421), Acute Lymphoblastic Leukemia (EFO_0000220), Mastocytosis (EFO_0009001), Systemic Mastocytosis (MONDO_0016586), Acute Myeloid Leukemia (EFO_0000222), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_5665', 'drugName': 'Midostaurin', 'tradeNames_string': 'Rydapt', 'drugSynonyms_string': 'CGP 41251, CGP-41251, Midostaurin, NSC-656576, NVP-PKC412, PKC 412, PKC-412, Pkc-412', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Liver Disease (EFO_0001421), Acute Lymphoblastic Leukemia (EFO_0000220), Mastocytosis (EFO_0009001), Systemic Mastocytosis (MONDO_0016586), Acute Myeloid Leukemia (EFO_0000222), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_5668', 'drugName': 'Midostaurin', 'tradeNames_string': 'Rydapt', 'drugSynonyms_string': 'CGP 41251, CGP-41251, Midostaurin, NSC-656576, NVP-PKC412, PKC 412, PKC-412, Pkc-412', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Liver Disease (EFO_0001421), Acute Lymphoblastic Leukemia (EFO_0000220), Mastocytosis (EFO_0009001), Systemic Mastocytosis (MONDO_0016586), Acute Myeloid Leukemia (EFO_0000222), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_5666', 'drugName': 'Midostaurin', 'tradeNames_string': 'Rydapt', 'drugSynonyms_string': 'CGP 41251, CGP-41251, Midostaurin, NSC-656576, NVP-PKC412, PKC 412, PKC-412, Pkc-412', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Liver Disease (EFO_0001421), Acute Lymphoblastic Leukemia (EFO_0000220), Mastocytosis (EFO_0009001), Systemic Mastocytosis (MONDO_0016586), Acute Myeloid Leukemia (EFO_0000222), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.922 | Q17 | What gene does the drug Mepazine target? | The drug Mepazine targets the gene MALT1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mepazine%" OR LOWER(tradeNames_string) LIKE "%mepazine%" OR LOWER(drugSynonyms_string) LIKE "%mepazine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1830', 'drugName': 'Mepazine', 'tradeNames_string': '', 'drugSynonyms_string': 'III-2318, Lacumin, Mepasin, Mepazin, Mepazine base, Meprazine, Mesapin, Nothiazine, P-391, Pacatal, Pacatal base, Pacatol, Pakatal, Paxital, Pecatal, Pecazine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MALT1 (ENSG00000172175)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1820', 'drugName': 'Mepazine Acetate', 'tradeNames_string': '', 'drugSynonyms_string': 'Mepazine acetate, NND 1964, Pecazine acetate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MALT1 (ENSG00000172175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1679 | Q17 | What gene does the drug Pentazocine Lactate target? | The drug Pentazocine Lactate targets the gene SIGMAR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pentazocine lactate%" OR LOWER(tradeNames_string) LIKE "%pentazocine lactate%" OR LOWER(drugSynonyms_string) LIKE "%pentazocine lactate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_652', 'drugName': 'Pentazocine Lactate', 'tradeNames_string': 'Talwin', 'drugSynonyms_string': 'Pentazocine lactate, Talwin (lactate)', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SIGMAR1 (ENSG00000147955)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1272 | Q17 | What gene does the drug Fluspirilene target? | The drug Fluspirilene targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fluspirilene%" OR LOWER(tradeNames_string) LIKE "%fluspirilene%" OR LOWER(drugSynonyms_string) LIKE "%fluspirilene%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_899', 'drugName': 'Fluspirilene', 'tradeNames_string': 'Imap, Redeptin', 'drugSynonyms_string': 'Fluspirilene, Imap, MCN-JR-6218, R 6218, R-6218, Redeptin', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Dementia (HP_0000726), Anxiety (EFO_0005230), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1094 | Q17 | What gene does the drug Rafabegron target? | The drug Rafabegron is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ADRB3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rafabegron%" OR LOWER(tradeNames_string) LIKE "%rafabegron%" OR LOWER(drugSynonyms_string) LIKE "%rafabegron%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2385', 'drugName': 'Rafabegron', 'tradeNames_string': '', 'drugSynonyms_string': 'AD-9677, Aj-9677, Rafabegron, TAK-677', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.389 | Q17 | What gene does the drug Meclofenamic Acid target? | The drug Meclofenamic Acid targets 3 genes: PTGS2, PTGS1 and ALOX5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%meclofenamic acid%" OR LOWER(tradeNames_string) LIKE "%meclofenamic acid%" OR LOWER(drugSynonyms_string) LIKE "%meclofenamic acid%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3725', 'drugName': 'Meclofenamate Sodium', 'tradeNames_string': 'Meclodium, Meclofenamate sodium, Meclomen', 'drugSynonyms_string': 'CL-583.NA SALT, Meclofenamate sodium, Meclofenamate sodium anhydrous, Meclofenamate sodium hydrate, Meclofenamic acid sodium, NSC-757088, Sodium meclofenamate, Sodium meclofenamate monohydrate', 'linkedDiseasesDrug_string': 'Osteoarthritis (MONDO_0005178), Juvenile Idiopathic Arthritis (EFO_0002609), Fever (HP_0001945), Dysmenorrhea (HP_0100607), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3724', 'drugName': 'Meclofenamate Sodium', 'tradeNames_string': 'Meclodium, Meclofenamate sodium, Meclomen', 'drugSynonyms_string': 'CL-583.NA SALT, Meclofenamate sodium, Meclofenamate sodium anhydrous, Meclofenamate sodium hydrate, Meclofenamic acid sodium, NSC-757088, Sodium meclofenamate, Sodium meclofenamate monohydrate', 'linkedDiseasesDrug_string': 'Osteoarthritis (MONDO_0005178), Juvenile Idiopathic Arthritis (EFO_0002609), Fever (HP_0001945), Dysmenorrhea (HP_0100607), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5035', 'drugName': 'Meclofenamic Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-583, CL-583, INF 4668, INF-4668, Meclodium, Meclofenamate, Meclofenamic acid, Meclomen, NSC-95309', 'linkedDiseasesDrug_string': 'Rheumatic Disease (EFO_0005755), Osteoarthritis (MONDO_0005178), Arthralgia (HP_0002829), Juvenile Idiopathic Arthritis (EFO_0002609), Fever (HP_0001945), Dysmenorrhea (HP_0100607), Rheumatoid Arthritis (EFO_0000685), Myalgia (HP_0003326)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5034', 'drugName': 'Meclofenamic Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-583, CL-583, INF 4668, INF-4668, Meclodium, Meclofenamate, Meclofenamic acid, Meclomen, NSC-95309', 'linkedDiseasesDrug_string': 'Rheumatic Disease (EFO_0005755), Osteoarthritis (MONDO_0005178), Arthralgia (HP_0002829), Juvenile Idiopathic Arthritis (EFO_0002609), Fever (HP_0001945), Dysmenorrhea (HP_0100607), Rheumatoid Arthritis (EFO_0000685), Myalgia (HP_0003326)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.841 | Q17 | What gene does the drug Cedazuridine target? | The drug Cedazuridine targets the gene CDA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cedazuridine%" OR LOWER(tradeNames_string) LIKE "%cedazuridine%" OR LOWER(drugSynonyms_string) LIKE "%cedazuridine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2765', 'drugName': 'Cedazuridine', 'tradeNames_string': '', 'drugSynonyms_string': 'ASTX-727 COMPONENT CEDAZURIDINE, ASTX727 COMPONENT CEDAZURIDINE, Cedazuridine, E-7727, E7727', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Acute Myeloid Leukemia (EFO_0000222), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Myelodysplastic Syndrome (EFO_0000198), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Carcinoma (EFO_0001663)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CDA (ENSG00000158825)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.774 | Q17 | What gene does the drug Hydroxyamphetamine Hydrobromide target? | The drug Hydroxyamphetamine Hydrobromide targets 9 genes: ADRA2A, ADRB1, ADRA2C, ADRA1A, ADRA1D, ADRA1B, ADRB3, ADRA2B and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydroxyamphetamine hydrobromide%" OR LOWER(tradeNames_string) LIKE "%hydroxyamphetamine hydrobromide%" OR LOWER(drugSynonyms_string) LIKE "%hydroxyamphetamine hydrobromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2950', 'drugName': 'Hydroxyamphetamine Hydrobromide', 'tradeNames_string': 'Paredrine', 'drugSynonyms_string': 'Hydroxyamfetamine hbr, Hydroxyamfetamine hydrobromide, Hydroxyamphetamine hbr, Hydroxyamphetamine hydrobromide, Hyroxyamfetamine hydrobromide, NSC-61065, Oxamphetamine hydrobromide, Phenol, 4-(2-aminopropyl)-, hbr', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1969, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1805 | Q17 | What gene does the drug Anileridine Hydrochloride target? | The drug Anileridine Hydrochloride targets 2 genes: OPRK1 and OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%anileridine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%anileridine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%anileridine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4594', 'drugName': 'Anileridine Hydrochloride', 'tradeNames_string': 'Leritine', 'drugSynonyms_string': 'Aldine, Anileridine dihydrochloride, Anileridine hcl, Anileridine hydrochloride, Anileridine hydrochloride cii, Apodol, Leritine dihydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4595', 'drugName': 'Anileridine Hydrochloride', 'tradeNames_string': 'Leritine', 'drugSynonyms_string': 'Aldine, Anileridine dihydrochloride, Anileridine hcl, Anileridine hydrochloride, Anileridine hydrochloride cii, Apodol, Leritine dihydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1992 | Q17 | What gene does the drug Delucemine target? | The drug Delucemine is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 7 genes: GRIN2B, GRIN2A, GRIN3A, GRIN2D, GRIN3B, GRIN1 and GRIN2C | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%delucemine%" OR LOWER(tradeNames_string) LIKE "%delucemine%" OR LOWER(drugSynonyms_string) LIKE "%delucemine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5026', 'drugName': 'Delucemine', 'tradeNames_string': '', 'drugSynonyms_string': 'Delucemine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': -1, 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1066 | Q17 | What gene does the drug Paroxetine target? | The drug Paroxetine targets the gene SLC6A4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%paroxetine%" OR LOWER(tradeNames_string) LIKE "%paroxetine%" OR LOWER(drugSynonyms_string) LIKE "%paroxetine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4720', 'drugName': 'Paroxetine Hydrochloride', 'tradeNames_string': 'Paroxetine hydrochloride, Paxil, Paxil cr, Seroxat', 'drugSynonyms_string': 'NSC-758654, Paroxetine HCl, Paroxetine hydrochloride, Paroxetine hydrochloride anhydrous', 'linkedDiseasesDrug_string': 'Post-Traumatic Stress Disorder (EFO_0001358), Unipolar Depression (EFO_0003761), Anxiety Disorder (EFO_0006788), Obsessive-Compulsive Disorder (EFO_0004242), Menopause (EFO_0003922), Anxiety (EFO_0005230), Major Depressive Disorder (MONDO_0002009), Panic Disorder (EFO_0004262), Depressive Disorder (MONDO_0002050), Social Anxiety Disorder (EFO_1001917)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5200', 'drugName': 'Paroxetine', 'tradeNames_string': 'Paxil [as hydrochloride]', 'drugSynonyms_string': '(-)3s,4r-paroxetine, Arketis, Arotin, BRL 29060, BRL-29060, Besitram, Casbol, Daparox, Fg-7051, Frosinor, Motivan, Parogen, Paroxetine, Paxil, Paxpar, Pexeva, Xetanor', 'linkedDiseasesDrug_string': 'Anxiety Disorder (EFO_0006788), Agoraphobia (EFO_1001872), Panic Disorder (EFO_0004262), Idiopathic Pulmonary Fibrosis (EFO_0000768), Hot Flashes (HP_0031217), Post-Traumatic Stress Disorder (EFO_0001358), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Fibromyalgia (EFO_0005687), Anovulation (MONDO_0002775), Obsessive-Compulsive Disorder (EFO_0004242), Menopause (EFO_0003922), Myocardial Infarction (EFO_0000612), Generalized Anxiety Disorder (EFO_1001892), Chronic Hepatitis C Virus Infection (EFO_0004220), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Rheumatoid Arthritis (EFO_0000685), Social Anxiety Disorder (EFO_1001917), Alcohol Dependence (MONDO_0007079), Unipolar Depression (EFO_0003761), Tinnitus (HP_0000360), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5494', 'drugName': 'Paroxetine Mesylate', 'tradeNames_string': 'Brisdelle, Pexeva', 'drugSynonyms_string': 'Mesafem, PO-T.MES, POT.MES, Paroxetine mesilate, Paroxetine mesylate, Paroxetine methanesulfonate, Paroxetine methanesulphonate', 'linkedDiseasesDrug_string': 'Menopause (EFO_0003922), Hot Flashes (HP_0031217)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3442', 'drugName': 'Paroxetine Hydrochloride Hemihydrate', 'tradeNames_string': '', 'drugSynonyms_string': 'BRL29060A, Brl29060a, Paroxetine hydrochloride, Paroxetine hydrochloride hemihydrate, Paroxetine hydrochloride hydrate', 'linkedDiseasesDrug_string': 'Social Anxiety Disorder (EFO_1001917)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.58 | Q17 | What gene does the drug Izokibep target? | The drug Izokibep is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IL17A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%izokibep%" OR LOWER(tradeNames_string) LIKE "%izokibep%" OR LOWER(drugSynonyms_string) LIKE "%izokibep%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5580', 'drugName': 'Izokibep', 'tradeNames_string': '', 'drugSynonyms_string': 'ABY-035, Aby-035, Aby-035/afo2, Aby035, IMG-020, Izokibep', 'linkedDiseasesDrug_string': 'Uveitis (EFO_1001231), Psoriasis (EFO_0000676), Ankylosing Spondylitis (EFO_0003898), Psoriatic Arthritis (EFO_0003778), Hidradenitis Suppurativa (EFO_1000710)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL17A (ENSG00000112115)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1688 | Q17 | What gene does the drug Olmesartan Medoxomil target? | The drug Olmesartan Medoxomil targets the gene AGTR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%olmesartan medoxomil%" OR LOWER(tradeNames_string) LIKE "%olmesartan medoxomil%" OR LOWER(drugSynonyms_string) LIKE "%olmesartan medoxomil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2021', 'drugName': 'Olmesartan Medoxomil', 'tradeNames_string': 'Benicar, Olmesartan medoxomil, Olmetec', 'drugSynonyms_string': 'CS-866, NSC-758924, Olmesartan medoxomil', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Diabetic Nephropathy (EFO_0000401), Stroke (EFO_0000712), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Essential Hypertension (MONDO_0001134), Glomerulonephritis (MONDO_0002462), Kidney Disease (EFO_0003086), Proteinuria (HP_0000093), Myocardial Infarction (EFO_0000612), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4635', 'drugName': 'Olmesartan', 'tradeNames_string': '', 'drugSynonyms_string': 'NSC-759810, Olmesartan, Olmesartan medoxomil impurity, olmesartan-, RNH-6270', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Essential Hypertension (MONDO_0001134), Hypertension (EFO_0000537), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1955 | Q17 | What gene does the drug Amifampridine target? | The drug Amifampridine targets 40 genes: KCNB1, KCND2, KCNA7, KCNG3, KCNA4, KCNQ1, KCNQ3, KCNA1, KCNC4, KCNS1, KCNG2, KCNA6, KCNV2, KCNA5, KCNH2, KCNS3, KCNQ4, KCND3, KCNG1, KCNB2, KCNH6, KCNC3, KCNG4, KCNF1, KCNH8, KCNS2, KCNA3, KCNQ2, KCNH4, KCNA10, KCNC2, KCNC1, KCNH1, KCNH3, KCNV1, KCNQ5, KCND1, KCNA2, KCNH7 and KCNH5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amifampridine%" OR LOWER(tradeNames_string) LIKE "%amifampridine%" OR LOWER(drugSynonyms_string) LIKE "%amifampridine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3435', 'drugName': 'Amifampridine Phosphate', 'tradeNames_string': 'Firdapse', 'drugSynonyms_string': '3,4-DAPP, Amifampridine phosphate, DAPP, Zenas', 'linkedDiseasesDrug_string': 'Myasthenia Gravis (EFO_0004991), Brugada Syndrome (MONDO_0015263), Spinal Muscular Atrophy (EFO_0008525), Muscle Atrophy (EFO_0009851)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'numberLinkedTargets': 40}, {'UUID': 'DrugGeneTargets_v2_5420', 'drugName': 'Amifampridine', 'tradeNames_string': 'Ruzurgi', 'drugSynonyms_string': '3,4-DAP, 3,4-Diammoniopyridinium, 4-DAP, Amifampridine, DAP, Dynamine, NSC-521760, Pyridine-3,4-Diamine', 'linkedDiseasesDrug_string': 'Botulism (EFO_0005542), Multiple Sclerosis (MONDO_0005301), Brugada Syndrome (MONDO_0015263), Spinal Muscular Atrophy (EFO_0008525), Myasthenia Gravis (EFO_0004991), Muscle Atrophy (EFO_0009851)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'numberLinkedTargets': 40}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1218 | Q17 | What gene does the drug Brimonidine Tartrate target? | The drug Brimonidine Tartrate targets 3 genes: ADRA2A, ADRA2C and ADRA2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%brimonidine tartrate%" OR LOWER(tradeNames_string) LIKE "%brimonidine tartrate%" OR LOWER(drugSynonyms_string) LIKE "%brimonidine tartrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4923', 'drugName': 'Brimonidine Tartrate', 'tradeNames_string': 'Alphagan, Alphagan p, Brimonidine tartrate, Brymont, Lumify, Mirvaso, Qoliana', 'drugSynonyms_string': 'AGN 190342-LF, AGN-190342-LF, AGN-190342LF, Brimonidine d-tartrate, Brimonidine tartrate, Bromoxidine tartrate, Cd-07805, OCU-300, OCU300, UK-14304-18, UK-1430418', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Flushing (HP_0031284), Rosacea (EFO_1000760), Presbyopia (MONDO_0001330), Hand-Foot Syndrome (EFO_1001893), Open-Angle Glaucoma (EFO_0004190), Hypertension (EFO_0000537), Erythema (HP_0010783), Dry Eye Syndrome (EFO_1000906), Hyperemia (EFO_0003822), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041), Alcohol-Related Disorders (MONDO_0021698), Corneal Edema (EFO_1000879)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1680 | Q17 | What gene does the drug Carboprost Tromethamine target? | The drug Carboprost Tromethamine targets the gene PTGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%carboprost tromethamine%" OR LOWER(tradeNames_string) LIKE "%carboprost tromethamine%" OR LOWER(drugSynonyms_string) LIKE "%carboprost tromethamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2928', 'drugName': 'Carboprost Tromethamine', 'tradeNames_string': 'Hemabate', 'drugSynonyms_string': 'Carboprost trometamol, Carboprost trometanol, Carboprost tromethamine, Carboprost tromethamine salt, U-32,921E, U-32921E', 'linkedDiseasesDrug_string': 'Postpartum Hemorrhage (EFO_0009579), Hemorrhage (MP_0001914)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1975 | Q17 | What gene does the drug Metoclopramide target? | The drug Metoclopramide targets 3 genes: HTR3A, HTR4 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%metoclopramide%" OR LOWER(tradeNames_string) LIKE "%metoclopramide%" OR LOWER(drugSynonyms_string) LIKE "%metoclopramide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3506', 'drugName': 'Metoclopramide', 'tradeNames_string': '', 'drugSynonyms_string': 'Clopra, Clopra-"Yellow", Elieten, Maxolon, Methoxyclopramide, Metoclopramide, Reglan, Terperan', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Orthostatic Hypotension (EFO_0005252), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Kidney Failure (EFO_1002048), Post Operative Nausea And Vomiting (EFO_0004888), Injury (EFO_0000546), Hypoglycemia (HP_0001943), Myelodysplastic Syndrome (EFO_0000198), Gastroparesis (EFO_1000948), Gastrointestinal Disease (EFO_0010282), Headache (HP_0002315), Gastroschisis (EFO_1000949), Gastroenteritis (EFO_1001463), Sepsis (HP_0100806), Intestinal Obstruction (MONDO_0004565), Orthostatic Intolerance (EFO_1000645), Hyperemesis Gravidarum (EFO_1000971), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Nausea And Vomiting (HP_0002017), Gastrointestinal Hemorrhage (HP_0002239), Vomiting (HP_0002013), Anorexia (HP_0002039)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5204', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_string': '"clopra-""yellow""", Clopra, Clopra-"Yellow", Gastrese l.a., Gastrobid continus, Gastroflux, Gastromax, Gimoti, Maxolon, Maxolon sr, Metoclomex, Metoclopramide hydrochloride, Metoclopramide intensol, Metox, Metozolv odt, Metramid, Mygdalon, Parmid, Primperan, Reglan, Reglan odt', 'drugSynonyms_string': 'AHR-3070-C, Metipamid, Metoclopramide dihydrochloride monohydrate, Metoclopramide hcl monohydrate, Metoclopramide hydrochloride, Metoclopramide hydrochloride monohydrate, Metoclopramide monohydrochloride monohydrate, Metoclopramidi hydrochloridum, NSC-757117', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Nausea And Vomiting (HP_0002017), Kidney Failure (EFO_1002048), Post Operative Nausea And Vomiting (EFO_0004888), Vomiting (HP_0002013), Anorexia (HP_0002039), Gastroparesis (EFO_1000948)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5203', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_string': '"clopra-""yellow""", Clopra, Clopra-"Yellow", Gastrese l.a., Gastrobid continus, Gastroflux, Gastromax, Gimoti, Maxolon, Maxolon sr, Metoclomex, Metoclopramide hydrochloride, Metoclopramide intensol, Metox, Metozolv odt, Metramid, Mygdalon, Parmid, Primperan, Reglan, Reglan odt', 'drugSynonyms_string': 'AHR-3070-C, Metipamid, Metoclopramide dihydrochloride monohydrate, Metoclopramide hcl monohydrate, Metoclopramide hydrochloride, Metoclopramide hydrochloride monohydrate, Metoclopramide monohydrochloride monohydrate, Metoclopramidi hydrochloridum, NSC-757117', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Nausea And Vomiting (HP_0002017), Kidney Failure (EFO_1002048), Post Operative Nausea And Vomiting (EFO_0004888), Vomiting (HP_0002013), Anorexia (HP_0002039), Gastroparesis (EFO_1000948)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3504', 'drugName': 'Metoclopramide', 'tradeNames_string': '', 'drugSynonyms_string': 'Clopra, Clopra-"Yellow", Elieten, Maxolon, Methoxyclopramide, Metoclopramide, Reglan, Terperan', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Orthostatic Hypotension (EFO_0005252), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Kidney Failure (EFO_1002048), Post Operative Nausea And Vomiting (EFO_0004888), Injury (EFO_0000546), Hypoglycemia (HP_0001943), Myelodysplastic Syndrome (EFO_0000198), Gastroparesis (EFO_1000948), Gastrointestinal Disease (EFO_0010282), Headache (HP_0002315), Gastroschisis (EFO_1000949), Gastroenteritis (EFO_1001463), Sepsis (HP_0100806), Intestinal Obstruction (MONDO_0004565), Orthostatic Intolerance (EFO_1000645), Hyperemesis Gravidarum (EFO_1000971), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Nausea And Vomiting (HP_0002017), Gastrointestinal Hemorrhage (HP_0002239), Vomiting (HP_0002013), Anorexia (HP_0002039)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3505', 'drugName': 'Metoclopramide', 'tradeNames_string': '', 'drugSynonyms_string': 'Clopra, Clopra-"Yellow", Elieten, Maxolon, Methoxyclopramide, Metoclopramide, Reglan, Terperan', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Orthostatic Hypotension (EFO_0005252), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Kidney Failure (EFO_1002048), Post Operative Nausea And Vomiting (EFO_0004888), Injury (EFO_0000546), Hypoglycemia (HP_0001943), Myelodysplastic Syndrome (EFO_0000198), Gastroparesis (EFO_1000948), Gastrointestinal Disease (EFO_0010282), Headache (HP_0002315), Gastroschisis (EFO_1000949), Gastroenteritis (EFO_1001463), Sepsis (HP_0100806), Intestinal Obstruction (MONDO_0004565), Orthostatic Intolerance (EFO_1000645), Hyperemesis Gravidarum (EFO_1000971), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Nausea And Vomiting (HP_0002017), Gastrointestinal Hemorrhage (HP_0002239), Vomiting (HP_0002013), Anorexia (HP_0002039)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5205', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_string': '"clopra-""yellow""", Clopra, Clopra-"Yellow", Gastrese l.a., Gastrobid continus, Gastroflux, Gastromax, Gimoti, Maxolon, Maxolon sr, Metoclomex, Metoclopramide hydrochloride, Metoclopramide intensol, Metox, Metozolv odt, Metramid, Mygdalon, Parmid, Primperan, Reglan, Reglan odt', 'drugSynonyms_string': 'AHR-3070-C, Metipamid, Metoclopramide dihydrochloride monohydrate, Metoclopramide hcl monohydrate, Metoclopramide hydrochloride, Metoclopramide hydrochloride monohydrate, Metoclopramide monohydrochloride monohydrate, Metoclopramidi hydrochloridum, NSC-757117', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Nausea And Vomiting (HP_0002017), Kidney Failure (EFO_1002048), Post Operative Nausea And Vomiting (EFO_0004888), Vomiting (HP_0002013), Anorexia (HP_0002039), Gastroparesis (EFO_1000948)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.213 | Q17 | What gene does the drug Apalutamide target? | The drug Apalutamide targets the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%apalutamide%" OR LOWER(tradeNames_string) LIKE "%apalutamide%" OR LOWER(drugSynonyms_string) LIKE "%apalutamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6164', 'drugName': 'Apalutamide', 'tradeNames_string': 'Erleada', 'drugSynonyms_string': 'ARN-509, Apalutamide, Arn-509, JNJ-56021927', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Liver Disease (EFO_0001421), Metastatic Prostate Cancer (EFO_0000196), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1534 | Q17 | What gene does the drug Argatroban target? | The drug Argatroban targets the gene F2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%argatroban%" OR LOWER(tradeNames_string) LIKE "%argatroban%" OR LOWER(drugSynonyms_string) LIKE "%argatroban%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2622', 'drugName': 'Argatroban', 'tradeNames_string': 'Acova, Argatroban, Argatroban in dextrose, Argatroban in sodium chloride', 'drugSynonyms_string': 'Argatroban, Argatroban anhydrous, Argatroban hydrate, Argatroban monohydrate, Argipidine, DK-7419, GN-1600, GN1600, MCI-9038, MD-805', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Thrombocytopenia (HP_0001873), Ischemic Stroke (HP_0002140), Hemorrhagic Disease (MONDO_0002243), Thrombotic Disease (MONDO_0000831), Intermediate Coronary Syndrome (EFO_1000985)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F2 (ENSG00000180210)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1135 | Q17 | What gene does the drug Butorphanol Tartrate target? | The drug Butorphanol Tartrate targets 2 genes: OPRK1 and OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%butorphanol tartrate%" OR LOWER(tradeNames_string) LIKE "%butorphanol tartrate%" OR LOWER(drugSynonyms_string) LIKE "%butorphanol tartrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1672', 'drugName': 'Butorphanol Tartrate', 'tradeNames_string': 'Butorphanol tartrate, Butorphanol tartrate preservative free, Stadol, Stadol ns, Stadol preservative free, Torbugesic, Torbutrol', 'drugSynonyms_string': 'Butorphanol tartrate, Butorphanol tartrate civ, Dolorex, LEVO-BC-2627 TARTRATE, Torbugesic, Torbutrol', 'linkedDiseasesDrug_string': 'Drug Dependence (EFO_0003890)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1673', 'drugName': 'Butorphanol Tartrate', 'tradeNames_string': 'Butorphanol tartrate, Butorphanol tartrate preservative free, Stadol, Stadol ns, Stadol preservative free, Torbugesic, Torbutrol', 'drugSynonyms_string': 'Butorphanol tartrate, Butorphanol tartrate civ, Dolorex, LEVO-BC-2627 TARTRATE, Torbugesic, Torbutrol', 'linkedDiseasesDrug_string': 'Drug Dependence (EFO_0003890)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.131 | Q17 | What gene does the drug Camicinal target? | The drug Camicinal is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MLNR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%camicinal%" OR LOWER(tradeNames_string) LIKE "%camicinal%" OR LOWER(drugSynonyms_string) LIKE "%camicinal%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4697', 'drugName': 'Camicinal', 'tradeNames_string': '', 'drugSynonyms_string': 'Camicinal, GSK-962040, GSK-962040B, GSK962040, GSK962040B, Gsk962040', 'linkedDiseasesDrug_string': 'Gastroparesis (EFO_1000948)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MLNR (ENSG00000102539)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.819 | Q17 | What gene does the drug Vinflunine target? | The drug Vinflunine targets 15 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vinflunine%" OR LOWER(tradeNames_string) LIKE "%vinflunine%" OR LOWER(drugSynonyms_string) LIKE "%vinflunine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_974', 'drugName': 'Vinflunine', 'tradeNames_string': '', 'drugSynonyms_string': 'Vinflunine', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Head And Neck Carcinoma (MONDO_0002038), Urogenital Neoplasm (EFO_0003863), Breast Cancer (MONDO_0007254), Penile Neoplasm (EFO_1001094), Small Cell Lung Carcinoma (EFO_0000702), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Urinary Bladder Carcinoma (MONDO_0004986), Prostate Cancer (MONDO_0008315), Transitional Cell Carcinoma (EFO_1000601), Urothelial Carcinoma (EFO_0008528), Gastric Cancer (MONDO_0001056)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1282 | Q17 | What gene does the drug Racecadotril target? | The drug Racecadotril targets the gene MME. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%racecadotril%" OR LOWER(tradeNames_string) LIKE "%racecadotril%" OR LOWER(drugSynonyms_string) LIKE "%racecadotril%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5090', 'drugName': 'Racecadotril', 'tradeNames_string': 'Hidrasec', 'drugSynonyms_string': 'Acetorphan, NSC-759828, Racecadotril, Tiorfan, Tiorfix', 'linkedDiseasesDrug_string': 'Diarrhea (HP_0002014), Diarrhea, Infantile (EFO_1001306)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MME (ENSG00000196549)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1872 | Q17 | What gene does the drug Sibutramine Hydrochloride target? | The drug Sibutramine Hydrochloride targets 3 genes: SLC6A4, SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sibutramine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%sibutramine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%sibutramine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2809', 'drugName': 'Sibutramine Hydrochloride', 'tradeNames_string': 'Meridia', 'drugSynonyms_string': 'BTS 54524, BTS-54524, NSC-758928, Sibutramine hcl, Sibutramine hydrochloride, Sibutramine hydrochloride civ, Sibutramine hydrochloride hydrate, Sibutramine hydrochloride monohydrate', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.438 | Q17 | What gene does the drug Triptorelin target? | The drug Triptorelin targets the gene GNRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%triptorelin%" OR LOWER(tradeNames_string) LIKE "%triptorelin%" OR LOWER(drugSynonyms_string) LIKE "%triptorelin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4710', 'drugName': 'Triptorelin Pamoate', 'tradeNames_string': 'Trelstar, Triptodur kit', 'drugSynonyms_string': 'Salvacyl, Triptorelin (as embonate), Triptorelin embonate, Triptorelin pamoate', 'linkedDiseasesDrug_string': 'Central Precocious Puberty (EFO_0009029), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Endometriosis (EFO_0001065), Precocious Puberty (MONDO_0000088), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3677', 'drugName': 'Triptorelin', 'tradeNames_string': 'Decapeptyl, Decapeptyl sr, Gonapeptyl depot', 'drugSynonyms_string': 'AY-25650, Arvekap, CL 118,532, CL-118532, Triptodur, Triptorelin, Tryptorelin, WY-42462', 'linkedDiseasesDrug_string': 'Central Precocious Puberty (EFO_0009029), Adenomyosis (EFO_1001757), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Infertility (EFO_0000545), Lymphoma (EFO_0000574), Hiv-1 Infection (EFO_0000180), Salivary Gland Cancer (MONDO_0004669), Ovarian Hyperstimulation Syndrome (MONDO_0011972), Endometriosis (EFO_0001065), Precocious Puberty (MONDO_0000088), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.417 | Q17 | What gene does the drug Lanadelumab target? | The drug Lanadelumab targets the gene KLKB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lanadelumab%" OR LOWER(tradeNames_string) LIKE "%lanadelumab%" OR LOWER(drugSynonyms_string) LIKE "%lanadelumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3309', 'drugName': 'Lanadelumab', 'tradeNames_string': 'Takhzyro', 'drugSynonyms_string': 'DX-2930, Lanadelumab, Lanadelumab (shp643), Lanadelumab flyo, Lanadelumab-flyo, SHP-643, Tak-743', 'linkedDiseasesDrug_string': 'Covid-19 (MONDO_0100096), Angioedema (EFO_0005532), Injury (EFO_0000546), Hypotension (EFO_0005251), Hereditary Angioedema (MONDO_0019623)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KLKB1 (ENSG00000164344)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1504 | Q17 | What gene does the drug Nemiralisib target? | The drug Nemiralisib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PIK3CD. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nemiralisib%" OR LOWER(tradeNames_string) LIKE "%nemiralisib%" OR LOWER(drugSynonyms_string) LIKE "%nemiralisib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2005', 'drugName': 'Gsk-2269557', 'tradeNames_string': '', 'drugSynonyms_string': 'GSK-2269557, GSK2269557, Gsk-2269557, Nemiralisib hydrochloride', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CD (ENSG00000171608)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2646', 'drugName': 'Nemiralisib', 'tradeNames_string': '', 'drugSynonyms_string': 'GSK-2269557, GSK-2269557 FREE BASE, GSK-2269557A, GSK2269557A, Nemiralisib', 'linkedDiseasesDrug_string': 'Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CD (ENSG00000171608)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.234 | Q17 | What gene does the drug Erlosamide target? | The drug Erlosamide targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%erlosamide%" OR LOWER(tradeNames_string) LIKE "%erlosamide%" OR LOWER(drugSynonyms_string) LIKE "%erlosamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4004', 'drugName': 'Erlosamide', 'tradeNames_string': 'Lacosamide, Vimpat', 'drugSynonyms_string': '(r)-lacosamide 1, ADD 243037, ADD-243037, Erlosamide, Lacosamide, Lacosamide cv, SPM 927, SPM-927', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Central Nervous System Cancer (EFO_0000326), Status Epilepticus (EFO_0008526), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Fibromyalgia (EFO_0005687), Partial Epilepsy (EFO_0004263), Epilepsy (EFO_0000474), Seizure (HP_0001250), Brain Neoplasm (EFO_0003833), Glioma (EFO_0005543), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Osteoarthritis (MONDO_0005178), Diabetic Neuropathy (EFO_1000783), Amyotrophic Lateral Sclerosis (MONDO_0004976), Postherpetic Neuralgia (MONDO_0041052), Kidney Disease (EFO_0003086), Primary Erythermalgia (MONDO_0007571), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1708 | Q17 | What gene does the drug Moc31-Pe target? | The drug Moc31-Pe is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene EPCAM. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%moc31-pe%" OR LOWER(tradeNames_string) LIKE "%moc31-pe%" OR LOWER(drugSynonyms_string) LIKE "%moc31-pe%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1481', 'drugName': 'Moc31-Pe', 'tradeNames_string': '', 'drugSynonyms_string': 'MOC31-PE, Moc31-pe', 'linkedDiseasesDrug_string': 'Carcinoma (EFO_0000313)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'EPCAM (ENSG00000119888)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.895 | Q17 | What gene does the drug Prednicarbate target? | The drug Prednicarbate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prednicarbate%" OR LOWER(tradeNames_string) LIKE "%prednicarbate%" OR LOWER(drugSynonyms_string) LIKE "%prednicarbate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3323', 'drugName': 'Prednicarbate', 'tradeNames_string': 'Dermatop, Dermatop e emollient, Prednicarbate', 'drugSynonyms_string': 'HOE 777, HOE-777, LAS-189961, LAS-41003 COMPONENT PREDNICARBATE, LAS189961, NSC-760042, Prednicarbate, S 77 0777, S-77 0777, S-77-0777, S-770777', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Psoriasis (EFO_0000676), Multiple Sclerosis (MONDO_0005301), Allergic Rhinitis (EFO_0005854), Endocrine System Disease (EFO_0001379), Tinea Pedis (EFO_0007512), Juvenile Idiopathic Arthritis (EFO_0002609), Bursitis (MONDO_0002471), Atopic Eczema (EFO_0000274), Psoriatic Arthritis (EFO_0003778), Adrenal Gland Disease (EFO_0005539), Tenosynovitis (EFO_1001435), Peptic Ulcer (HP_0004398), Allergic Conjunctivitis (EFO_0007141), Brain Neoplasm (EFO_0003833), Inflammation (MP_0001845), Anemia (MONDO_0002280), Rheumatoid Arthritis (EFO_0000685), Eczema (HP_0000964), Osteoarthritis (MONDO_0005178), Skin Disease (EFO_0000701), Posterior Uveitis (EFO_1001119), Spondylitis (MONDO_0003937), Candidiasis (MONDO_0002026)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1625 | Q17 | What gene does the drug Odronextamab target? | The drug Odronextamab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: MS4A1, CD3E, CD3G and CD3D | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%odronextamab%" OR LOWER(tradeNames_string) LIKE "%odronextamab%" OR LOWER(drugSynonyms_string) LIKE "%odronextamab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1602', 'drugName': 'Odronextamab', 'tradeNames_string': '', 'drugSynonyms_string': 'Odronextamab, REGN-1979, REGN1979, Regn-1979, Regn1979', 'linkedDiseasesDrug_string': 'Neoplasm Of Mature B-Cells (EFO_0000096), Chronic Lymphocytic Leukemia (EFO_0000095), Lymphoma (EFO_0000574)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), MS4A1 (ENSG00000156738)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_1603', 'drugName': 'Odronextamab', 'tradeNames_string': '', 'drugSynonyms_string': 'Odronextamab, REGN-1979, REGN1979, Regn-1979, Regn1979', 'linkedDiseasesDrug_string': 'Neoplasm Of Mature B-Cells (EFO_0000096), Chronic Lymphocytic Leukemia (EFO_0000095), Lymphoma (EFO_0000574)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), MS4A1 (ENSG00000156738)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.699 | Q17 | What gene does the drug Oxyphenonium Bromide target? | The drug Oxyphenonium Bromide targets 2 genes: CHRM1 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxyphenonium bromide%" OR LOWER(tradeNames_string) LIKE "%oxyphenonium bromide%" OR LOWER(drugSynonyms_string) LIKE "%oxyphenonium bromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1163', 'drugName': 'Oxyphenonium Bromide', 'tradeNames_string': 'Antrenyl', 'drugSynonyms_string': 'Antrenil, BA-5473, C-5473, NSC-759248, Oxifenon, Oxyfenon, Oxyphenon, Oxyphenonium bromide, Spasmodin, Spasmophen', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1164', 'drugName': 'Oxyphenonium Bromide', 'tradeNames_string': 'Antrenyl', 'drugSynonyms_string': 'Antrenil, BA-5473, C-5473, NSC-759248, Oxifenon, Oxyfenon, Oxyphenon, Oxyphenonium bromide, Spasmodin, Spasmophen', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1769 | Q17 | What gene does the drug Bortezomib target? | The drug Bortezomib targets 38 genes: PSMD6, PSMC5, PSMB11, PSMA4, PSMC6, PSMC2, PSMB2, PSMA6, PSMA2, PSMD13, PSMB9, ADRM1, PSMD2, PSMB8, PSMB4, PSMD11, SEM1, PSMB10, PSMD14, PSMA3, PSMB1, PSMD4, PSMB3, PSMA5, PSMD12, PSMB6, PSMD7, PSMB5, PSMD8, PSMD1, PSMC4, PSMA1, PSMA8, PSMC3, PSMC1, PSMA7, PSMD3 and PSMB7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bortezomib%" OR LOWER(tradeNames_string) LIKE "%bortezomib%" OR LOWER(drugSynonyms_string) LIKE "%bortezomib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_559', 'drugName': 'Bortezomib', 'tradeNames_string': 'Velcade', 'drugSynonyms_string': 'Bortezomib, Bortezomib accord, Bortezomib hydrate, LDP-341, NSC-681239, PS-341, Velcade', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Bronchiolitis Obliterans (EFO_0007183), Lymphoid Neoplasm (EFO_0001642), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Uremia (EFO_1001226), Lung Adenocarcinoma (EFO_0000571), Urinary Bladder Carcinoma (MONDO_0004986), Castleman Disease (MONDO_0015564), Malt Lymphoma (EFO_0000191), Cervical Cancer (MONDO_0002974), Follicular Lymphoma (MONDO_0018906), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Lymphoma, Aids-Related (EFO_1001365), Classic Hodgkin Lymphoma (MONDO_0009348), Japanese Encephalitis (EFO_0007332), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Al Amyloidosis (MONDO_0019438), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Neuromyelitis Optica (EFO_0004256), Pure Red-Cell Aplasia (MONDO_0001705), Anaplastic Large Cell Lymphoma (EFO_0003032), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Prostate Carcinoma (EFO_0001663), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Bronchoalveolar Adenocarcinoma (EFO_0000308), Anaplastic Oligodendroglioma (EFO_0002501), Hodgkins Lymphoma (EFO_0000183), Salivary Gland Adenoid Cystic Carcinoma (MONDO_0003175), Chronic Kidney Disease (EFO_0003884), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Non-Small Cell Lung Carcinoma (EFO_0003060), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Asymptomatic Myeloma (EFO_0003073), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Plasmacytoma (EFO_0006738), Intrahepatic Cholangiocarcinoma (EFO_1001961), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Mycosis Fungoides (EFO_1001051), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Glioma (EFO_0005543), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Sarcoma (EFO_0000691), Primary Systemic Amyloidosis (MONDO_0017816), Lymphoproliferative Syndrome (MONDO_0016537), Amyloidosis (EFO_1001875), Ureter Cancer (MONDO_0008627), Graft Versus Host Disease (MONDO_0013730), Adenoid Cystic Carcinoma (EFO_0000231), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Plasma Cell Leukemia (EFO_0006475), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Urethra Cancer (MONDO_0004192), Refractory Anemia With Excess Blasts (EFO_0003811), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'numberLinkedTargets': 38}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.301 | Q17 | What gene does the drug Etretinate target? | The drug Etretinate targets 6 genes: RARG, RARA, RARB, RXRB, RXRG and RXRA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%etretinate%" OR LOWER(tradeNames_string) LIKE "%etretinate%" OR LOWER(drugSynonyms_string) LIKE "%etretinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_343', 'drugName': 'Etretinate', 'tradeNames_string': 'Tegison, Tigason', 'drugSynonyms_string': 'Acitretin related compound b, Ethyl etrinoate, Etretinate, NSC-297936, RO 10-9359, RO-10-9359, RO-109359', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RXRB (ENSG00000204231), RARG (ENSG00000172819), RXRG (ENSG00000143171), RARB (ENSG00000077092), RARA (ENSG00000131759), RXRA (ENSG00000186350)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1399 | Q17 | What gene does the drug Alclofenac target? | The drug Alclofenac targets the gene PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alclofenac%" OR LOWER(tradeNames_string) LIKE "%alclofenac%" OR LOWER(drugSynonyms_string) LIKE "%alclofenac%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3320', 'drugName': 'Alclofenac', 'tradeNames_string': 'Mervan', 'drugSynonyms_string': 'Alclofenac, W 7320', 'linkedDiseasesDrug_string': 'Rheumatic Disease (EFO_0005755)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1987 | Q17 | What gene does the drug Mecasermin Rinfabate target? | The drug Mecasermin Rinfabate targets the gene IGF1R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mecasermin rinfabate%" OR LOWER(tradeNames_string) LIKE "%mecasermin rinfabate%" OR LOWER(drugSynonyms_string) LIKE "%mecasermin rinfabate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_672', 'drugName': 'Mecasermin Rinfabate', 'tradeNames_string': 'Iplex, Somatokine', 'drugSynonyms_string': 'Mecasermin Rinfabate Recombinant, Mecasermin rinfabate, Mecasermin rinfabate recombinant, RHIGF-I/RHIGFBP-3', 'linkedDiseasesDrug_string': 'Myotonic Dystrophy (MONDO_0016107), Steinert Myotonic Dystrophy (Orphanet_273), Laron Syndrome (MONDO_0009877), Retinopathy Of Prematurity (EFO_1001158)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.102 | Q17 | What gene does the drug Tazarotene target? | The drug Tazarotene targets 3 genes: RARB, RARA and RARG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tazarotene%" OR LOWER(tradeNames_string) LIKE "%tazarotene%" OR LOWER(drugSynonyms_string) LIKE "%tazarotene%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5124', 'drugName': 'Tazarotene', 'tradeNames_string': 'Arazlo, Avage, Fabior, Tazorac, Zorac', 'drugSynonyms_string': 'AGN 190168, AGN-190168, Idp-123, Tazarotene', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Genetic Hypopigmentation Of The Skin (Orphanet_183469), Skin Carcinoma (EFO_0009259), Skin Disease (EFO_0000701), Acne (EFO_0003894), Cutaneous T-Cell Lymphoma (EFO_0002913), Lentigo (MONDO_0021582), Psoriasis Vulgaris (EFO_1001494)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RARG (ENSG00000172819), RARB (ENSG00000077092), RARA (ENSG00000131759)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.831 | Q17 | What gene does the drug Saxagliptin target? | The drug Saxagliptin targets the gene DPP4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%saxagliptin%" OR LOWER(tradeNames_string) LIKE "%saxagliptin%" OR LOWER(drugSynonyms_string) LIKE "%saxagliptin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6010', 'drugName': 'Saxagliptin', 'tradeNames_string': '', 'drugSynonyms_string': 'BMS-477118, BMS-477118-11, Saxagliptin', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Polycystic Ovary Syndrome (EFO_0000660), Abnormal Glucose Tolerance (EFO_0002546), Acute Myocardial Infarction (EFO_0008583), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2239', 'drugName': 'Saxagliptin Hydrochloride', 'tradeNames_string': 'Onglyza', 'drugSynonyms_string': 'Saxagliptin HCl, Saxagliptin hcl, Saxagliptin hydrochloride', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.